JP6030630B2 - 経口ペプチド送達のための脂肪酸アシル化アミノ酸 - Google Patents
経口ペプチド送達のための脂肪酸アシル化アミノ酸 Download PDFInfo
- Publication number
- JP6030630B2 JP6030630B2 JP2014504327A JP2014504327A JP6030630B2 JP 6030630 B2 JP6030630 B2 JP 6030630B2 JP 2014504327 A JP2014504327 A JP 2014504327A JP 2014504327 A JP2014504327 A JP 2014504327A JP 6030630 B2 JP6030630 B2 JP 6030630B2
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- amino acid
- pharmaceutical composition
- decanoyl
- dodecanoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001413 amino acids Chemical class 0.000 title claims description 292
- 108090000765 processed proteins & peptides Proteins 0.000 title description 203
- 235000001014 amino acid Nutrition 0.000 claims description 316
- 229940024606 amino acid Drugs 0.000 claims description 314
- 239000011734 sodium Substances 0.000 claims description 224
- 229910052708 sodium Inorganic materials 0.000 claims description 219
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 207
- -1 cationic amino acid Chemical group 0.000 claims description 160
- 239000008194 pharmaceutical composition Substances 0.000 claims description 137
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 133
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 105
- 108090001061 Insulin Proteins 0.000 claims description 94
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 80
- 229930195729 fatty acid Natural products 0.000 claims description 80
- 239000000194 fatty acid Substances 0.000 claims description 80
- 230000002209 hydrophobic effect Effects 0.000 claims description 80
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 70
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 68
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 66
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 64
- 125000004432 carbon atom Chemical group C* 0.000 claims description 58
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 50
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 48
- 229960003136 leucine Drugs 0.000 claims description 46
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 43
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 41
- 125000000539 amino acid group Chemical group 0.000 claims description 40
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 39
- 229960004295 valine Drugs 0.000 claims description 39
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 38
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 35
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 34
- 229960005190 phenylalanine Drugs 0.000 claims description 34
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 34
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 33
- 229960003767 alanine Drugs 0.000 claims description 33
- 235000004279 alanine Nutrition 0.000 claims description 33
- 229940071089 sarcosinate Drugs 0.000 claims description 33
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 32
- 239000004474 valine Substances 0.000 claims description 32
- 229960000310 isoleucine Drugs 0.000 claims description 30
- 229960001230 asparagine Drugs 0.000 claims description 27
- 239000002552 dosage form Substances 0.000 claims description 26
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 24
- 229960004452 methionine Drugs 0.000 claims description 24
- 229960002429 proline Drugs 0.000 claims description 24
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 claims description 24
- 230000002378 acidificating effect Effects 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 229940045944 sodium lauroyl glutamate Drugs 0.000 claims description 23
- 150000004665 fatty acids Chemical group 0.000 claims description 22
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 22
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 21
- 108700004121 sarkosyl Proteins 0.000 claims description 21
- 229940078455 sodium lauroyl aspartate Drugs 0.000 claims description 21
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 claims description 21
- 239000004473 Threonine Substances 0.000 claims description 20
- 229960005261 aspartic acid Drugs 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 229960002898 threonine Drugs 0.000 claims description 20
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 18
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 18
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 18
- 229960002989 glutamic acid Drugs 0.000 claims description 18
- 239000004220 glutamic acid Substances 0.000 claims description 18
- 229930182817 methionine Natural products 0.000 claims description 18
- 229960004799 tryptophan Drugs 0.000 claims description 18
- 235000013922 glutamic acid Nutrition 0.000 claims description 17
- 235000003704 aspartic acid Nutrition 0.000 claims description 16
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 16
- 229940049906 glutamate Drugs 0.000 claims description 16
- 229930195712 glutamate Natural products 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 15
- 229940009098 aspartate Drugs 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-L cysteinate(2-) Chemical compound [S-]CC(N)C([O-])=O XUJNEKJLAYXESH-UHFFFAOYSA-L 0.000 claims description 13
- 230000003111 delayed effect Effects 0.000 claims description 13
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 13
- 229940079781 sodium cocoyl glutamate Drugs 0.000 claims description 13
- OUYCCCASQSFEME-UHFFFAOYSA-L tyrosinate(2-) Chemical compound [O-]C(=O)C(N)CC1=CC=C([O-])C=C1 OUYCCCASQSFEME-UHFFFAOYSA-L 0.000 claims description 13
- KZSNJWFQEVHDMF-UHFFFAOYSA-M valinate Chemical compound CC(C)C(N)C([O-])=O KZSNJWFQEVHDMF-UHFFFAOYSA-M 0.000 claims description 13
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 12
- QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 11
- QIVBCDIJIAJPQS-UHFFFAOYSA-M tryptophanate Chemical compound C1=CC=C2C(CC(N)C([O-])=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-M 0.000 claims description 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-M prolinate Chemical compound [O-]C(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-M 0.000 claims description 10
- IKGKWKGYFJBGQJ-UHFFFAOYSA-M sodium;2-(dodecanoylamino)acetate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCC([O-])=O IKGKWKGYFJBGQJ-UHFFFAOYSA-M 0.000 claims description 10
- OBACDZMAJJOBJC-LBPRGKRZSA-N (2s)-2-(decanoylamino)pentanedioic acid Chemical compound CCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O OBACDZMAJJOBJC-LBPRGKRZSA-N 0.000 claims description 9
- AVBJHQDHVYGQLS-AWEZNQCLSA-N (2s)-2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-AWEZNQCLSA-N 0.000 claims description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 235000018417 cysteine Nutrition 0.000 claims description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 9
- 229960001153 serine Drugs 0.000 claims description 9
- 229960004441 tyrosine Drugs 0.000 claims description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-M serinate Chemical compound OCC(N)C([O-])=O MTCFGRXMJLQNBG-UHFFFAOYSA-M 0.000 claims description 8
- CZJJQSUIALCKCZ-NSHDSACASA-N (2r)-2-(decanoylamino)-3-sulfanylpropanoic acid Chemical compound CCCCCCCCCC(=O)N[C@@H](CS)C(O)=O CZJJQSUIALCKCZ-NSHDSACASA-N 0.000 claims description 7
- DJPVXOYGQKTRPA-KRWDZBQOSA-N (2s)-2-(decanoylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound CCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DJPVXOYGQKTRPA-KRWDZBQOSA-N 0.000 claims description 7
- AFYMQZVURIZOSA-NSHDSACASA-N (2s)-2-(decanoylamino)-3-hydroxypropanoic acid Chemical compound CCCCCCCCCC(=O)N[C@@H](CO)C(O)=O AFYMQZVURIZOSA-NSHDSACASA-N 0.000 claims description 7
- KMJDEJIZLJQIQI-NSHDSACASA-N (2s)-2-(decanoylamino)propanoic acid Chemical compound CCCCCCCCCC(=O)N[C@@H](C)C(O)=O KMJDEJIZLJQIQI-NSHDSACASA-N 0.000 claims description 7
- XGFQVJQXCLZRFH-ZDUSSCGKSA-N (2s)-2-(dodecanoylamino)-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@@H](CO)C(O)=O XGFQVJQXCLZRFH-ZDUSSCGKSA-N 0.000 claims description 7
- WQHXCNGQDLRDMP-INIZCTEOSA-N (2s)-2-(dodecanoylamino)-3-methylbutanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@@H](C(C)C)C(O)=O WQHXCNGQDLRDMP-INIZCTEOSA-N 0.000 claims description 7
- UYTOHYBIBPDOKX-ZDUSSCGKSA-N (2s)-2-(dodecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@@H](C)C(O)=O UYTOHYBIBPDOKX-ZDUSSCGKSA-N 0.000 claims description 7
- MZUBOXLGCNTCGH-LBPRGKRZSA-N (2s)-5-amino-2-(decanoylamino)-5-oxopentanoic acid Chemical compound CCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(N)=O MZUBOXLGCNTCGH-LBPRGKRZSA-N 0.000 claims description 7
- BHPUZXHJBNPVQQ-HIFRSBDPSA-N (2s,3r)-2-(dodecanoylamino)-3-hydroxybutanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@@H]([C@@H](C)O)C(O)=O BHPUZXHJBNPVQQ-HIFRSBDPSA-N 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 7
- DJPVXOYGQKTRPA-UHFFFAOYSA-N N-decanoyl-L-tyrosine Natural products CCCCCCCCCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 DJPVXOYGQKTRPA-UHFFFAOYSA-N 0.000 claims description 7
- SVQAZCRYIXURJT-UHFFFAOYSA-N N-dodecanoyl-L-tyrosine Natural products CCCCCCCCCCCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 SVQAZCRYIXURJT-UHFFFAOYSA-N 0.000 claims description 7
- 108010077895 Sarcosine Proteins 0.000 claims description 7
- SVQAZCRYIXURJT-IBGZPJMESA-N n-dodecanoyl-l-tyrosine Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SVQAZCRYIXURJT-IBGZPJMESA-N 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-M phenylalaninate Chemical compound [O-]C(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-M 0.000 claims description 7
- AJWFQCNUNFFTHX-HNNXBMFYSA-N (2s)-1-dodecanoylpyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1CCC[C@H]1C(O)=O AJWFQCNUNFFTHX-HNNXBMFYSA-N 0.000 claims description 6
- AYFVGKNJGXCSDI-IBGZPJMESA-N (2s)-2-(decanoylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](NC(=O)CCCCCCCCC)C(O)=O)=CNC2=C1 AYFVGKNJGXCSDI-IBGZPJMESA-N 0.000 claims description 6
- BPZWMTJHFOPXCT-KRWDZBQOSA-N (2s)-2-(decanoylamino)-3-phenylpropanoic acid Chemical compound CCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BPZWMTJHFOPXCT-KRWDZBQOSA-N 0.000 claims description 6
- KDQCSJBLQLMYLH-AWEZNQCLSA-N (2s)-2-(decanoylamino)-4-methylpentanoic acid Chemical compound CCCCCCCCCC(=O)N[C@H](C(O)=O)CC(C)C KDQCSJBLQLMYLH-AWEZNQCLSA-N 0.000 claims description 6
- MTYLJFSVEPZMIY-NRFANRHFSA-N (2s)-2-(dodecanoylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](NC(=O)CCCCCCCCCCC)C(O)=O)=CNC2=C1 MTYLJFSVEPZMIY-NRFANRHFSA-N 0.000 claims description 6
- IVNYHFWUYNDIDY-RDJZCZTQSA-N (2s,3s)-2-(dodecanoylamino)-3-methylpentanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)[C@@H](C)CC IVNYHFWUYNDIDY-RDJZCZTQSA-N 0.000 claims description 6
- GDJYINIIGLKESK-ZDUSSCGKSA-N (2s)-4-amino-2-(dodecanoylamino)-4-oxobutanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC(N)=O GDJYINIIGLKESK-ZDUSSCGKSA-N 0.000 claims description 5
- BVQYSBCMUYMJKE-ZOWNYOTGSA-N N[C@@H](CO)C(=O)OC(CCCCCCCCCCC)=O.[Na] Chemical compound N[C@@H](CO)C(=O)OC(CCCCCCCCCCC)=O.[Na] BVQYSBCMUYMJKE-ZOWNYOTGSA-N 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- SZJKBLZPBALIGH-ZDUSSCGKSA-N (2r)-2-(dodecanoylamino)-3-sulfanylpropanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@@H](CS)C(O)=O SZJKBLZPBALIGH-ZDUSSCGKSA-N 0.000 claims description 3
- USMCNVFGYLZLGM-AWEZNQCLSA-N (2s)-5-amino-2-(dodecanoylamino)-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(N)=O USMCNVFGYLZLGM-AWEZNQCLSA-N 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- VLKIFCBXANYYCK-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]acetate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CC([O-])=O VLKIFCBXANYYCK-GMFCBQQYSA-M 0.000 claims description 3
- RKQUHHNIJVGMIG-IBGZPJMESA-N (2s)-2-(dodecanoylamino)-3-phenylpropanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 RKQUHHNIJVGMIG-IBGZPJMESA-N 0.000 claims description 2
- CDOCNWRWMUMCLP-INIZCTEOSA-N (2s)-2-(dodecanoylamino)-4-methylpentanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC(C)C CDOCNWRWMUMCLP-INIZCTEOSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 229940073490 sodium glutamate Drugs 0.000 claims description 2
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 claims description 2
- IEXXLSKKBWIDAC-ZOWNYOTGSA-M sodium;(3s)-3-(dodecanoylamino)-4-hydroxy-4-oxobutanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CC(O)=O IEXXLSKKBWIDAC-ZOWNYOTGSA-M 0.000 claims 2
- CGRAZTUFJGMPDO-RSAXXLAASA-N (2s)-2-(decylamino)-4-methylpentanoic acid;sodium Chemical compound [Na].CCCCCCCCCCN[C@H](C(O)=O)CC(C)C CGRAZTUFJGMPDO-RSAXXLAASA-N 0.000 claims 1
- PFSGUIFKRGNSHV-HNNXBMFYSA-N (2s)-2-(dodecanoylamino)-4-methylsulfanylbutanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCSC PFSGUIFKRGNSHV-HNNXBMFYSA-N 0.000 claims 1
- ACMIJDVJWLMBCX-PXAZEXFGSA-N 4-[(3ar,6ar)-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrol-5-yl]-6-fluoro-n-methyl-2-(2-methylpyrimidin-5-yl)oxy-9h-pyrimido[4,5-b]indol-8-amine Chemical compound CNC1=CC(F)=CC(C2=C(N3C[C@@H]4NCC[C@@H]4C3)N=3)=C1NC2=NC=3OC1=CN=C(C)N=C1 ACMIJDVJWLMBCX-PXAZEXFGSA-N 0.000 claims 1
- SEEVXRGPKFUXRF-UHFFFAOYSA-M CCCCCCCCCCCC(OS(CS([O-])(=O)=O)(=O)=O)=O.[Na+] Chemical compound CCCCCCCCCCCC(OS(CS([O-])(=O)=O)(=O)=O)=O.[Na+] SEEVXRGPKFUXRF-UHFFFAOYSA-M 0.000 claims 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 150000003871 sulfonates Chemical class 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 278
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 277
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 191
- 229940083542 sodium Drugs 0.000 description 187
- 235000018102 proteins Nutrition 0.000 description 172
- 102000004169 proteins and genes Human genes 0.000 description 172
- 108090000623 proteins and genes Proteins 0.000 description 171
- 239000007788 liquid Substances 0.000 description 116
- 230000001225 therapeutic effect Effects 0.000 description 97
- 239000007787 solid Substances 0.000 description 80
- 102000004196 processed proteins & peptides Human genes 0.000 description 64
- 125000005313 fatty acid group Chemical group 0.000 description 63
- 102000004877 Insulin Human genes 0.000 description 60
- 239000004094 surface-active agent Substances 0.000 description 60
- 229940125396 insulin Drugs 0.000 description 57
- 229920000642 polymer Polymers 0.000 description 56
- 235000013772 propylene glycol Nutrition 0.000 description 44
- 229920001184 polypeptide Polymers 0.000 description 36
- 239000002202 Polyethylene glycol Substances 0.000 description 33
- 229920001223 polyethylene glycol Polymers 0.000 description 33
- 229920000223 polyglycerol Polymers 0.000 description 32
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 31
- 239000007901 soft capsule Substances 0.000 description 31
- 239000002904 solvent Substances 0.000 description 31
- 239000004026 insulin derivative Substances 0.000 description 29
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 28
- 239000007902 hard capsule Substances 0.000 description 26
- 238000009472 formulation Methods 0.000 description 25
- 238000012453 sprague-dawley rat model Methods 0.000 description 24
- 238000005516 engineering process Methods 0.000 description 22
- 210000001630 jejunum Anatomy 0.000 description 22
- 229920000136 polysorbate Polymers 0.000 description 21
- 239000008363 phosphate buffer Substances 0.000 description 20
- 229920001213 Polysorbate 20 Polymers 0.000 description 19
- WUIVWRSHESPBPX-GXKRWWSZSA-L disodium;(2s)-2-(dodecanoylamino)butanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CC([O-])=O WUIVWRSHESPBPX-GXKRWWSZSA-L 0.000 description 19
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 19
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 19
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 18
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 16
- 239000012736 aqueous medium Substances 0.000 description 16
- 229920002521 macromolecule Polymers 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 239000004530 micro-emulsion Substances 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 13
- 102220208083 rs749414711 Human genes 0.000 description 13
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 12
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 229940068977 polysorbate 20 Drugs 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 10
- 229920000053 polysorbate 80 Polymers 0.000 description 10
- 229940077092 sodium myristoyl glutamate Drugs 0.000 description 10
- FCBUGCHAVCFTHW-NTISSMGPSA-N sodium;(2s)-2-(tetradecanoylamino)pentanedioic acid Chemical compound [Na].CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O FCBUGCHAVCFTHW-NTISSMGPSA-N 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- ZNYIJXQYUNSKDX-NTISSMGPSA-M sodium;hydron;(2s)-2-(tetradecanoylamino)pentanedioate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O ZNYIJXQYUNSKDX-NTISSMGPSA-M 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000002702 enteric coating Substances 0.000 description 8
- 238000009505 enteric coating Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- QKHBMQWPOUUMQZ-BDQAORGHSA-M sodium;hydron;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC([O-])=O QKHBMQWPOUUMQZ-BDQAORGHSA-M 0.000 description 8
- WSJCTRAECJWNOS-NSHDSACASA-N (2s)-2-(decanoylamino)butanedioic acid Chemical compound CCCCCCCCCC(=O)N[C@H](C(O)=O)CC(O)=O WSJCTRAECJWNOS-NSHDSACASA-N 0.000 description 7
- 229920003134 Eudragit® polymer Polymers 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 229960003511 macrogol Drugs 0.000 description 7
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 7
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 7
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 239000004064 cosurfactant Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229960002885 histidine Drugs 0.000 description 6
- 239000007908 nanoemulsion Substances 0.000 description 6
- 239000002736 nonionic surfactant Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 239000003961 penetration enhancing agent Substances 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 5
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 239000004395 L-leucine Substances 0.000 description 5
- 229920002675 Polyoxyl Polymers 0.000 description 5
- 229920001219 Polysorbate 40 Polymers 0.000 description 5
- 239000004147 Sorbitan trioleate Substances 0.000 description 5
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 235000019337 sorbitan trioleate Nutrition 0.000 description 5
- 229960000391 sorbitan trioleate Drugs 0.000 description 5
- BKVABDKAKQZLJF-AWEZNQCLSA-N (2s)-2-(decanoylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound CCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKVABDKAKQZLJF-AWEZNQCLSA-N 0.000 description 4
- JQYKKDIUABIHQQ-FYZYNONXSA-N (2s)-2-(dodecanoylamino)-3-phenylpropanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JQYKKDIUABIHQQ-FYZYNONXSA-N 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- FKHDBTXXRZLESW-NBLXOJGSSA-N [Na].CCCCCCCCCCCC(=O)N[C@H](C(O)=O)[C@@H](C)CC Chemical compound [Na].CCCCCCCCCCCC(=O)N[C@H](C(O)=O)[C@@H](C)CC FKHDBTXXRZLESW-NBLXOJGSSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 4
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 4
- 229940101027 polysorbate 40 Drugs 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- KQYAHAGYCNNBCD-FYZYNONXSA-M sodium;(2s)-2-(dodecanoylamino)-3-phenylpropanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KQYAHAGYCNNBCD-FYZYNONXSA-M 0.000 description 4
- 229940035044 sorbitan monolaurate Drugs 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- IGMAHSCLECVIDN-INIZCTEOSA-N (2s)-2-(dodecanoylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 IGMAHSCLECVIDN-INIZCTEOSA-N 0.000 description 3
- SQLZSCZPPIRBFA-NTISSMGPSA-N (2s)-2-(dodecanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 SQLZSCZPPIRBFA-NTISSMGPSA-N 0.000 description 3
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 3
- 0 CC(C(O*)=O)N(*)C(*)=O Chemical compound CC(C(O*)=O)N(*)C(*)=O 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 description 3
- 229940122618 Trypsin inhibitor Drugs 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229940068965 polysorbates Drugs 0.000 description 3
- 102220066003 rs771633824 Human genes 0.000 description 3
- 229940065859 sodium cocoyl glycinate Drugs 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical group CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 229920001304 Solutol HS 15 Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- CXFXWQIBTPWSLJ-RSAXXLAASA-N [Na].CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCSC Chemical compound [Na].CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCSC CXFXWQIBTPWSLJ-RSAXXLAASA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 102220352928 c.35C>A Human genes 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000001246 colloidal dispersion Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 108010050259 insulin degludec Proteins 0.000 description 2
- 229960004225 insulin degludec Drugs 0.000 description 2
- 238000005511 kinetic theory Methods 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- MKRYOOFLLNYJNB-UHFFFAOYSA-N octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.CCCCCCCC(O)=O MKRYOOFLLNYJNB-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 102220010259 rs202247806 Human genes 0.000 description 2
- 102200082905 rs35203747 Human genes 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 2
- LFUXMTKAILZVTA-ZOWNYOTGSA-M sodium;(2s)-2-(dodecanoylamino)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@@H](C)C([O-])=O LFUXMTKAILZVTA-ZOWNYOTGSA-M 0.000 description 2
- QCEMAUIWBQOBKI-PBCQUBLHSA-M sodium;(2s,3r)-2-(dodecanoylamino)-3-hydroxybutanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@@H]([C@@H](C)O)C([O-])=O QCEMAUIWBQOBKI-PBCQUBLHSA-M 0.000 description 2
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- VCRXMSMANOGRCM-ZDUSSCGKSA-N (2s)-2-(dodecanoylamino)butanedioic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC(O)=O VCRXMSMANOGRCM-ZDUSSCGKSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- KZRXPHCVIMWWDS-AWEZNQCLSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O KZRXPHCVIMWWDS-AWEZNQCLSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 229940114069 12-hydroxystearate Drugs 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- CDOCNWRWMUMCLP-UHFFFAOYSA-N 2-(dodecanoylamino)-4-methylpentanoic acid Chemical compound CCCCCCCCCCCC(=O)NC(C(O)=O)CC(C)C CDOCNWRWMUMCLP-UHFFFAOYSA-N 0.000 description 1
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- BMYCCWYAFNPAQC-UHFFFAOYSA-N 2-[dodecyl(methyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCN(C)CC(O)=O BMYCCWYAFNPAQC-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- GSWYUZQBLVUEPH-UHFFFAOYSA-N 3-(azaniumylmethyl)benzoate Chemical compound NCC1=CC=CC(C(O)=O)=C1 GSWYUZQBLVUEPH-UHFFFAOYSA-N 0.000 description 1
- GAYBJDZLMVRVKL-UHFFFAOYSA-N 4-methyl-2-(tetradecanoylamino)pentanoic acid Chemical compound CCCCCCCCCCCCCC(=O)NC(C(O)=O)CC(C)C GAYBJDZLMVRVKL-UHFFFAOYSA-N 0.000 description 1
- 108700004929 A8H,B25N,B27E,desB30- insulin Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 101150023320 B16R gene Proteins 0.000 description 1
- 102220494599 Casein kinase I isoform delta_A13K_mutation Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229930195715 D-glutamine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- YUAGKNPTYWDXOT-FYZYNONXSA-N N[C@@H](CC1=CC=CC=C1)C(=O)OC(CCCCCCCCCCC)=O.[Na] Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)OC(CCCCCCCCCCC)=O.[Na] YUAGKNPTYWDXOT-FYZYNONXSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- DIOYAVUHUXAUPX-KHPPLWFESA-N Oleoyl sarcosine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CC(O)=O DIOYAVUHUXAUPX-KHPPLWFESA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002507 Poloxamer 124 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102220493212 Small nuclear ribonucleoprotein E_A14R_mutation Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- XTSBBRPVKYLEDV-RSAXXLAASA-N [Na].CCCCCCCCCCCC(=O)OC(=O)[C@@H]1CCCN1 Chemical compound [Na].CCCCCCCCCCCC(=O)OC(=O)[C@@H]1CCCN1 XTSBBRPVKYLEDV-RSAXXLAASA-N 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 102220351917 c.13A>G Human genes 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940071124 cocoyl glutamate Drugs 0.000 description 1
- 229940065856 cocoyl glycinate Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- RGOLHHQRNQPCOF-UHFFFAOYSA-N decanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.CCCCCCCCCC(O)=O RGOLHHQRNQPCOF-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000004491 dispersible concentrate Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 229940051858 insulin degludec and liraglutide Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940071085 lauroyl glutamate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-M methioninate Chemical compound CSCCC(N)C([O-])=O FFEARJCKVFRZRR-UHFFFAOYSA-M 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940093448 poloxamer 124 Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 102200068096 rs104894363 Human genes 0.000 description 1
- 102200033149 rs387906943 Human genes 0.000 description 1
- 102220056958 rs730880941 Human genes 0.000 description 1
- 102220217844 rs747356389 Human genes 0.000 description 1
- 102220320752 rs747356389 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- SPZDDBQUYSHZDF-RSAXXLAASA-M sodium;(2s)-1-dodecanoylpyrrolidine-2-carboxylate Chemical compound [Na+].CCCCCCCCCCCC(=O)N1CCC[C@H]1C([O-])=O SPZDDBQUYSHZDF-RSAXXLAASA-M 0.000 description 1
- LPIMQMRHMBZVRI-BOXHHOBZSA-M sodium;(2s)-2-(dodecanoylamino)-3-(1h-indol-3-yl)propanoate Chemical compound [Na+].C1=CC=C2C(C[C@H](NC(=O)CCCCCCCCCCC)C([O-])=O)=CNC2=C1 LPIMQMRHMBZVRI-BOXHHOBZSA-M 0.000 description 1
- RZLORCNPOWHAMO-FYZYNONXSA-M sodium;(2s)-2-(dodecanoylamino)-3-(4-hydroxyphenyl)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 RZLORCNPOWHAMO-FYZYNONXSA-M 0.000 description 1
- WSGBFSXSXAKJJC-ZOWNYOTGSA-M sodium;(2s)-2-(dodecanoylamino)-3-hydroxypropanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@@H](CO)C([O-])=O WSGBFSXSXAKJJC-ZOWNYOTGSA-M 0.000 description 1
- UEWBTMYWRIIMEJ-NTISSMGPSA-M sodium;(2s)-2-(dodecanoylamino)-3-methylbutanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@@H](C(C)C)C([O-])=O UEWBTMYWRIIMEJ-NTISSMGPSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11162411.0 | 2011-04-14 | ||
| EP11162411 | 2011-04-14 | ||
| US201161477719P | 2011-04-21 | 2011-04-21 | |
| US61/477,719 | 2011-04-21 | ||
| PCT/EP2012/056708 WO2012140155A1 (en) | 2011-04-14 | 2012-04-12 | Fatty acid acylated amino acids for oral peptide delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512366A JP2014512366A (ja) | 2014-05-22 |
| JP2014512366A5 JP2014512366A5 (OSRAM) | 2015-05-28 |
| JP6030630B2 true JP6030630B2 (ja) | 2016-11-24 |
Family
ID=44343059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504327A Expired - Fee Related JP6030630B2 (ja) | 2011-04-14 | 2012-04-12 | 経口ペプチド送達のための脂肪酸アシル化アミノ酸 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140056953A1 (OSRAM) |
| EP (1) | EP2696847A1 (OSRAM) |
| JP (1) | JP6030630B2 (OSRAM) |
| CN (1) | CN103458873B (OSRAM) |
| WO (1) | WO2012140155A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150250882A1 (en) * | 2012-10-17 | 2015-09-10 | Novo Nordisk Health Care Ag | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery |
| WO2014060472A1 (en) * | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| EP2908846A1 (en) * | 2012-10-17 | 2015-08-26 | Novo Nordisk A/S | Fatty acid acylated d-amino acids for oral peptide delivery |
| WO2015162195A1 (en) * | 2014-04-23 | 2015-10-29 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| ES2630106T3 (es) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
| CN104961687B (zh) * | 2015-06-03 | 2017-07-25 | 苏州维泰生物技术有限公司 | 1,2‑二嗪衍生物及其制剂、用途 |
| CN111759823B (zh) * | 2015-09-17 | 2022-12-30 | 阿赖耶识（上海）生物技术有限公司 | 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用 |
| AU2016335287A1 (en) | 2015-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| JP6633777B2 (ja) | 2017-08-24 | 2020-01-22 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１組成物及びその使用 |
| TWI751379B (zh) | 2017-09-21 | 2022-01-01 | 奧孟亞股份有限公司 | 用於遞送胜肽之藥物組合物 |
| WO2019108739A1 (en) * | 2017-11-30 | 2019-06-06 | Dana-Farber Cancer Institute, Inc. | Chemical uncouplers of respiration and methods of use thereof |
| FR3075197B1 (fr) * | 2017-12-20 | 2019-11-15 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Nouvelle composition de lipoaminoacides et de diols, le procede pour leur preparation et composition cosmetique ou pharmaceutique en resultant |
| EP3773475A1 (en) | 2018-04-06 | 2021-02-17 | Cyprumed GmbH | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| CN116419750A (zh) | 2020-09-07 | 2023-07-11 | 西普鲁梅有限公司 | 改进的glp-1受体激动剂的药物制剂 |
| EP4180060A1 (en) * | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| CN119156221A (zh) | 2022-03-03 | 2024-12-17 | 西普鲁梅有限公司 | 治疗性肽和蛋白质的改进的口服药物制剂 |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2772168A (en) * | 1951-11-28 | 1956-11-27 | Colgate Palmolive Co | Fermentable carbohydrate food products |
| US4258029A (en) * | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
| US4749694A (en) * | 1984-04-26 | 1988-06-07 | Merck & Co., Inc. | Novel lysine esters used as absorption |
| US5270032A (en) * | 1990-10-04 | 1993-12-14 | The Research Foundation Of State University Of New York | Composition and method for the prevention and treatment of candidiasis |
| US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| US6624754B1 (en) * | 1998-01-20 | 2003-09-23 | Hoffman Resources Llc | Personal security and tracking system |
| FR2767064B1 (fr) * | 1997-08-07 | 1999-11-12 | Centre Nat Rech Scient | Procede de liberation d'un principe actif contenu dans une emulsion multiple |
| AU1262501A (en) | 1999-11-12 | 2001-05-30 | Pharmaderm Laboratories, Ltd. | Compositions for transdermal and transmucosal administration of therapeutic agents |
| FR2828102B1 (fr) * | 2001-03-28 | 2004-07-09 | Ifc Sa | Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes |
| US6951655B2 (en) | 2001-10-11 | 2005-10-04 | Imi Biomed, Inc. | Pro-micelle pharmaceutical compositions |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| US20050282756A1 (en) | 2004-06-18 | 2005-12-22 | Mehta Nozer M | Oral delivery of peptide pharmaceutical compositions |
| JP4147235B2 (ja) * | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置 |
| EP2074141B1 (en) | 2006-09-22 | 2016-08-10 | Novo Nordisk A/S | Protease resistant insulin analogues |
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| PT2910570T (pt) | 2008-03-18 | 2017-01-24 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
| US20110293714A1 (en) * | 2008-11-28 | 2011-12-01 | Novo Nordisk A/S | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
| JP5123922B2 (ja) | 2009-12-02 | 2013-01-23 | 独立行政法人科学技術振興機構 | 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系 |
-
2012
- 2012-04-12 CN CN201280017853.5A patent/CN103458873B/zh not_active Expired - Fee Related
- 2012-04-12 US US14/111,274 patent/US20140056953A1/en not_active Abandoned
- 2012-04-12 EP EP12713173.8A patent/EP2696847A1/en not_active Withdrawn
- 2012-04-12 WO PCT/EP2012/056708 patent/WO2012140155A1/en not_active Ceased
- 2012-04-12 JP JP2014504327A patent/JP6030630B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103458873A (zh) | 2013-12-18 |
| JP2014512366A (ja) | 2014-05-22 |
| CN103458873B (zh) | 2016-04-13 |
| WO2012140155A1 (en) | 2012-10-18 |
| US20140056953A1 (en) | 2014-02-27 |
| EP2696847A1 (en) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6030630B2 (ja) | 経口ペプチド送達のための脂肪酸アシル化アミノ酸 | |
| US20150273069A1 (en) | Fatty acid acylated amino acids for oral peptide delivery | |
| EP2514406A1 (en) | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier | |
| US20140255481A1 (en) | Pharmaceutical Compositions for Oral Administration of Insulin Peptides | |
| Noh et al. | Recent progress in hydrophobic ion-pairing and lipid-based drug delivery systems for enhanced oral delivery of biopharmaceuticals | |
| US20110293714A1 (en) | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides | |
| US20240041983A1 (en) | Improved pharmaceutical formulations of glp-1 receptor agonists | |
| ZA200600373B (en) | Use of calcitonin in osteoarthritis | |
| WO2011141685A2 (fr) | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants | |
| JP6285447B2 (ja) | 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸 | |
| WO2015162195A1 (en) | Fatty acid acylated amino acids for oral peptide delivery | |
| AU2010323117B2 (en) | Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion | |
| WO2022013306A1 (en) | Oral pharmaceutical compositions comprising lipid conjugates | |
| JP2007535545A (ja) | 難吸収性薬剤の経口投与のための製剤 | |
| TW201136582A (en) | Improved pharmaceutical compositions of aliskiren and methods of delivery | |
| Maher et al. | Formulation Strategies to Improve Oral Peptide Delivery: A Patent Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150408 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150408 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160506 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160711 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160926 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161020 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6030630 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |